|
Diagnosis
|
Subgroups
|
No. of subjects
|
Age (years)
|
Sex (M/F)
|
MMSE [NR]
|
CSF Aβ42
|
CSF t-tau
|
CSF p-tau
|
Years from diagnosis
|
Years of education
|
|---|
|
Control
|
N/A
|
50
|
64.06 ± 9.8 (25–83)
|
24/26
|
29.3 ± 1.0
|
N/A
|
N/A
|
N/A
|
N/A
|
16.44 ± 2.7
|
|
AD
|
N/A
|
50
|
67.8 ± 10.4 (53–87)
|
24/26
|
21.0 ± 5.6
|
145.7 ± 34.8
|
116.2 ± 68
|
45 ± 23.7
|
3.6 ± 2.2
|
16.5 ± 2.3
|
|
PD
|
Total
|
50
|
66.76 ± 7.7 (49–82)
|
35/15
|
28.9 ± 1.1 [11]
|
261.8 ± 49.8
|
43 ± 13.7
|
20.9 ± 7.4
|
10 ± 5.1
|
16.54 ± 2.2
|
|
Dementia
|
15
|
72.33 ± 6.1 (61–82)
|
11/4
|
27 [1]
|
N/A
|
N/A
|
N/A
|
11 ± 3.9
|
16.33 ± 2.8
|
|
MCI
|
8
|
68.37 ± 7.0 (54–77)
|
5/3
|
29 ± 0.8 [4]
|
N/A
|
N/A
|
N/A
|
10.4 ± 7.4
|
16.25 ± 1.7
|
|
FTD
|
Total
|
50
|
63.14 ± 6.9 (46–76)
|
28/22
|
24.1 ± 5.3 [46]
|
271.4 ± 52.3
|
62.2 ± 27.9
|
16.5 ± 7.8
|
3.2 ± 2.3
|
15.96 ± 3.1
|
|
bv
|
23
|
61.69 ± 6.3 (46–74)
|
15/8
|
25.3 ± 4.4
|
278.6 ± 52.3
|
57.2 ± 22.5
|
14.5 ± 4.6
|
2.7 ± 2.2
|
16.43 ± 3.0
|
|
PPA/Lgpen
|
1
|
70
|
1/0
|
22
| | | |
2
|
18
|
|
PPA/PNFA
|
8
|
67.75 ± 4.6 (61–75)
|
3/5
|
19.6 ± 9.18 [5]
|
269.9 ± 63.5
|
75.2 ± 35.2
|
14.6 ± 4.3
|
4.5 ± 2.1
|
15.2 ± 3.84
|
|
PPA/SD
|
8
|
61.25 ± 8.4 (49–76)
|
4/4
|
22.1 ± 5.19
|
286 ± 48.4
|
79.9 ± 36.6
|
15.9 ± 4.5
|
4 ± 3.0
|
17 ± 2.82
|
|
PSP
|
10
|
63.6 ± 7.51 (54–75)
|
5/5
|
25.6 ± 4.4
|
244.7 ± 46.0
|
50.6 ± 19.5
|
14.5 ± 4.6
|
2.7 ± 1.6
|
14.4 ± 2.99
|
|
ALS
|
Total
|
50
|
59.64 ± 10.8 (29–83)
|
36/14
|
24.8 ± 7.8 [16]
|
240.4 ± 76.3
|
71.1 ± 50.7
|
13.8 ± 6.8
|
1.8 ± 1.8
|
14.71 ± 2.9
|
|
With FTD
|
5
|
65.4 ± 9.18 (49–70)
|
4/1
|
14. 3 ± 12.0 [3]
|
222.4 ± 88.8
|
107 ± 62.1
|
19 ± 10.1
|
4 ± 4.4
|
15.8 ± 2.3
|
|
With MCI
|
3
|
57 ± 5.2 (54–63)
|
2/1
|
30 [1]
|
340 ± 3
|
66 ± 32
|
11.3 ± 0.6
|
1 ± 1
|
13.5 ± 7.8
|
-
Abbreviations: Aβ
42
Amyloid-β 42, AD Alzheimer’s disease, ALS Amyotrophic lateral sclerosis, FTD Frontotemporal dementia, PD Parkinson’s disease, M/F Male/female, MMSE Mini Mental State Examination, NR Number of research participants with Mini Mental State Examination reported (MMSE is reported for all participants in a subgroup [e.g., control] if no NR value is given), N/A Not available, bv Behavioral variant, PPA/Lgpen Primary progressive aphasia, logopenic variant, PPA/PNFA Primary progressive aphasia/progressive nonfluent aphasia, PPA/SD Primary progressive aphasia/semantic dementia, PSP Progressive supranuclear palsy, CSF Cerebrospinal fluid, MCI Mild cognitive impairment, p-tau Phosphorylated tau, t-tau Total tau
